• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Shivaani Kummar, Robert J. Kinders, +17 authors James H. Doroshow
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2009 (First Published: 1 June 2009)
  • PURPOSE We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was aContinue Reading
  • Neal E. Ready, Matthew D Hellmann, +25 authors Suresh S Ramalingam
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2019 (First Published: 20 April 2019)
  • PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non-small-cell lungContinue Reading
  • Shivaani Kummar, M. R. Escudero Gutiérrez, +18 authors Anthony J. Murgo
  • Medicine
  • European journal of cancer
  • 2010
  • PURPOSE Phase I dose-escalation study to determine the toxicity and maximum tolerated dose (MTD) of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein 90 (Hsp90)Continue Reading
  • Lihua Wang, Thomas D. Pfister, +8 authors Robert J. Kinders
  • Biology, Medicine
  • Clinical cancer research : an official journal of…
  • 2010 (First Published: 1 February 2010)
  • PURPOSE Circulating tumor cells (CTC) in peripheral blood of patients potentially represent a fraction of solid tumor cells available for more frequent pharmacodynamic assessment of drug action thanContinue Reading
  • Suresh Kumar Agarwal, Ahmed Hamed Salem, +6 authors Shekman L. Wong
  • Medicine
  • British journal of clinical pharmacology
  • 2017 (First Published: 1 April 2017)
  • AIMS To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax. METHODS Twelve patients with non‐HodgkinContinue Reading